• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      Almirall gets FDA approval for migraine drug

      Posted AtReuters.com

      MADRID, June 3 (Reuters) - Spanish pharmaceutical firm Almirall (ALM.MC: Quote, Profile, Research, Stock Buzz) on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.

      The drug -- marketed with U.S. partner Johnson & Johnson's (JNJ.N: Quote, Profile, Research, Stock Buzz) Ortho-McNeil Janssen Pharmaceuticals -- was already sold to treat migraines in adults, but is the first of its kind to be approved by the FDA for adolescents, Almirall said.

      "This is a huge step for Almirall and our North American partner as it shows our commitment to giving adolescents with migraines a treatment that has not existed to date," it said.

      Almirall's patent on Almotriptan in the United States has been extended to November 2015.

      June 04, 2009


      Share this Article!

    Back to top^